Drug
VTX-2337 clinical trials
Also written VTX-2337 and Motolimod.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 7
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 4
Celgene (5) · Ludwig Institute for Cancer Research (1) · University of Washington (1) · Gynecologic Oncology Group (1) · Presage Biosciences (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Nivolumab (2) · Cetuximab (1) · Liposomal doxorubicin (1) · Doxorubicin (1) · Paclitaxel (1) · Cyclophosphamide (1)
Studies
Open first, then newest update. How each study uses VTX-2337 is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck CancerTerminatedPhase 1CelgeneNCT03906526Written as VTX-2337
- Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian CancerCompletedPhase 1/2Ludwig Institute for Cancer ResearchNCT02431559Written as Motolimod
- Intratumoral Microdosing of Motolimod in HNSCCTerminatedEarly Phase 1Presage BiosciencesNCT04272333Written as Motolimod
- Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedPhase 2CelgeneNCT01836029Written as VTX-2337
- VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedPhase 2CelgeneNCT01666444Written as VTX-2337
- Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced CancerCompletedPhase 1CelgeneNCT00688415Written as VTX-2337
- VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell LymphomasTerminatedPhase 1/2CelgeneNCT01289210Written as VTX-2337 plus radiotherapy
- TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsTerminatedPhase 1Mayo ClinicNCT02650635Written as TLR8 Agonist VTX-2337
- TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and NeckCompletedPhase 1University of WashingtonNCT01334177Written as TLR8 agonist VTX-2337
- TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerCompletedPhase 1Gynecologic Oncology GroupNCT01294293Written as TLR8 Agonist VTX-2337